<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=213807269037206&ev=PageView&noscript=1">
Blog

Compliance In Focus

remote services

LEARN MORE ABOUT REMOTE SERVICES

Keep Your Clinical Trial Moving from a Distance

You want to keep your trial on track, but physical distancing and travel restrictions have made it difficult. Fortunately, IMARC has experience providing remote services.

FILTER BY:

Newest Post

Posted by Lindsey R. Friedrich on Tue, Feb 21, 2017

Maintaining Professionalism During a Conflict

Maintaining professionalism in a difficult situation is unfortunately something most professionals encounter during their career. Being able to keep calm and stay logical during these times is key to maintaining trust with a client, and helping them feel comfortable and confident to work with you to resolve the issue(s) at hand. For Clinical Research Associates (CRAs), diplomacy and tact are crucial since often they work in stressful situations where subjects’ health and safety are involved. Thus, it is important to understand the general principles that define professionalism and how to gain trust in a working relationship, maintain that trust to power through stressful situations, and “rise above the fray” when tensions are high. This blog will cover each of these aspects and will aim to provide you with the necessary tools to handle conflict and remain professional.

Topics: Clinical Research Associate, Professionalism

Posted by Tracey Tytko on Mon, Nov 06, 2017

The Future of the FDA: The Perception of a Clinical Research Associate

There are many stakeholders involved in conducting a clinical trial today; however, there can be many challenges to the infrastructure of running a clinical trial. Challenges that are seen with running medical device trials can vary anywhere from securing funding to lacking time and having dedicated study personnel. Another challenge that is faced is the time to market new devices that are ensured to have safety, quality and effectiveness. Although protecting human research subjects is the top of all priorities, can this regulatory pathway be shortened?

Topics: FDA, CDRH, Robert Califf, Clinical Research Associate